Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Antibody nanoparticle dispersions formed with mixtures of crowding molecules retain activity and in vivo bioavailability.

Miller MA, Khan TA, Kaczorowski KJ, Wilson BK, Dinin AK, Borwankar AU, Rodrigues MA, Truskett TM, Johnston KP, Maynard JA.

J Pharm Sci. 2012 Oct;101(10):3763-78. doi: 10.1002/jps.23256. Epub 2012 Jul 6.

2.

Concentrated dispersions of equilibrium protein nanoclusters that reversibly dissociate into active monomers.

Johnston KP, Maynard JA, Truskett TM, Borwankar AU, Miller MA, Wilson BK, Dinin AK, Khan TA, Kaczorowski KJ.

ACS Nano. 2012 Feb 28;6(2):1357-69. doi: 10.1021/nn204166z. Epub 2012 Jan 30.

PMID:
22260218
3.

Reversible self-association increases the viscosity of a concentrated monoclonal antibody in aqueous solution.

Liu J, Nguyen MD, Andya JD, Shire SJ.

J Pharm Sci. 2005 Sep;94(9):1928-40. Erratum in: J Pharm Sci. 2006 Jan;95(1):234-5.

PMID:
16052543
4.

Intermolecular Interactions and the Viscosity of Highly Concentrated Monoclonal Antibody Solutions.

Binabaji E, Ma J, Zydney AL.

Pharm Res. 2015 Sep;32(9):3102-9. doi: 10.1007/s11095-015-1690-6. Epub 2015 Apr 2.

PMID:
25832501
5.

An Approach to Mitigate Particle Formation on the Dilution of a Monoclonal Antibody Drug Product in an IV Administration Fluid.

Zheng S, Adams M, Mantri RV.

J Pharm Sci. 2016 Mar;105(3):1349-50. doi: 10.1016/j.xphs.2015.12.013. Epub 2016 Jan 30.

PMID:
26886343
6.

Understanding and modulating opalescence and viscosity in a monoclonal antibody formulation.

Salinas BA, Sathish HA, Bishop SM, Harn N, Carpenter JF, Randolph TW.

J Pharm Sci. 2010 Jan;99(1):82-93. doi: 10.1002/jps.21797.

7.

Viscosity-Lowering Effect of Amino Acids and Salts on Highly Concentrated Solutions of Two IgG1 Monoclonal Antibodies.

Wang S, Zhang N, Hu T, Dai W, Feng X, Zhang X, Qian F.

Mol Pharm. 2015 Dec 7;12(12):4478-87. doi: 10.1021/acs.molpharmaceut.5b00643. Epub 2015 Nov 12.

PMID:
26528726
8.

Crystalline monoclonal antibodies for subcutaneous delivery.

Yang MX, Shenoy B, Disttler M, Patel R, McGrath M, Pechenov S, Margolin AL.

Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):6934-9. Epub 2003 Jun 2.

9.

Prevention of stirring-induced microparticle formation in monoclonal antibody solutions.

Ishikawa T, Kobayashi N, Osawa C, Sawa E, Wakamatsu K.

Biol Pharm Bull. 2010;33(6):1043-6.

10.

Rapid analysis of antibody self-association in complex mixtures using immunogold conjugates.

Sule SV, Dickinson CD, Lu J, Chow CK, Tessier PM.

Mol Pharm. 2013 Apr 1;10(4):1322-31. doi: 10.1021/mp300524x. Epub 2013 Mar 8.

PMID:
23383873
11.

Rational design of viscosity reducing mutants of a monoclonal antibody: hydrophobic versus electrostatic inter-molecular interactions.

Nichols P, Li L, Kumar S, Buck PM, Singh SK, Goswami S, Balthazor B, Conley TR, Sek D, Allen MJ.

MAbs. 2015;7(1):212-30. doi: 10.4161/19420862.2014.985504.

12.

Application of melt extrusion in the development of a physically and chemically stable high-energy amorphous solid dispersion of a poorly water-soluble drug.

Lakshman JP, Cao Y, Kowalski J, Serajuddin AT.

Mol Pharm. 2008 Nov-Dec;5(6):994-1002. doi: 10.1021/mp8001073.

PMID:
19434852
13.

Structure-activity relationship for hydrophobic salts as viscosity-lowering excipients for concentrated solutions of monoclonal antibodies.

Guo Z, Chen A, Nassar RA, Helk B, Mueller C, Tang Y, Gupta K, Klibanov AM.

Pharm Res. 2012 Nov;29(11):3102-9. doi: 10.1007/s11095-012-0802-9. Epub 2012 Jun 13.

PMID:
22692671
14.

Viscosity of concentrated therapeutic protein compositions.

Jezek J, Rides M, Derham B, Moore J, Cerasoli E, Simler R, Perez-Ramirez B.

Adv Drug Deliv Rev. 2011 Oct;63(13):1107-17. doi: 10.1016/j.addr.2011.09.008. Review.

PMID:
22014592
15.

No Touching! Abrasion of Adsorbed Protein Is the Root Cause of Subvisible Particle Formation During Stirring.

Sediq AS, van Duijvenvoorde RB, Jiskoot W, Nejadnik MR.

J Pharm Sci. 2016 Feb;105(2):519-29. doi: 10.1016/j.xphs.2015.10.003. Epub 2016 Jan 12.

PMID:
26869415
16.

Prediction of colloidal stability of high concentration protein formulations.

Garidel P, Blume A, Wagner M.

Pharm Dev Technol. 2015 May;20(3):367-74. doi: 10.3109/10837450.2013.871032. Epub 2014 Jan 6.

PMID:
24392929
17.
18.

Investigating high-concentration monoclonal antibody powder suspension in nonaqueous suspension vehicles for subcutaneous injection.

Bowen M, Armstrong N, Maa YF.

J Pharm Sci. 2012 Dec;101(12):4433-43. doi: 10.1002/jps.23324. Epub 2012 Sep 21.

PMID:
23001898
19.

Application of a high-throughput screening procedure with PEG-induced precipitation to compare relative protein solubility during formulation development with IgG1 monoclonal antibodies.

Gibson TJ, Mccarty K, Mcfadyen IJ, Cash E, Dalmonte P, Hinds KD, Dinerman AA, Alvarez JC, Volkin DB.

J Pharm Sci. 2011 Mar;100(3):1009-21. doi: 10.1002/jps.22350. Epub 2010 Oct 25.

PMID:
21280052
20.

Supplemental Content

Support Center